Editorials

173 Is it AKI or Nonrecovery of Renal Function That Is Important for Long-Term Outcomes?
Steven G. Coca
See related article on page 194.

177 Basically, Dialysis Is Not Good Enough
Seth B. Furgeson and Isaac Teitelbaum
See related article on page 254.

179 Initiation of Dialysis at Higher Levels of Estimated GFR and Subsequent Withdrawal
Ann M. O’Hare, Elizabeth K. Vig, and Paul L. Hebert
See related article on page 265.

182 Pregnancy in Renal Transplant Recipients: More Questions Answered, Still More Asked
Michelle A. Josephson
See related article on page 290.

Original Articles

Acute Kidney Injury /Acute Renal Failure

184 Urinary Angiotensinogen and Risk of Severe AKI
Joseph L. Alge, Nithin Karakala, Benjamin A. Neely, Michael G. Janech, James A. Tumlin, Lakhmir S. Chawla, Andrew D. Shaw, and John M. Arthur, for the SAKInet Investigators

194 Association between AKI, Recovery of Renal Function, and Long-Term Outcomes after Hospital Discharge
Neesh Pannu, Matthew James, Brenda Hemmelgarn, and Scott Klarenbach, for the Alberta Kidney Disease Network
See related editorial on page 173.

Chronic Kidney Disease

203 Change in Cardiac Geometry and Function in CKD Children During Strict BP Control: A Randomized Study
Maria Chiara Matteucci, Marcello Chinali, Gabriele Rinelli, Elke Wühl, Aleksandra Zurowska, Marina Charbit, Giacomo Pongiglione, Franz Schaefer, and the ESCAPE Trial Group

Clinical Nephrology

211 Renal Function and Proteinuria after Successful Immunosuppressive Therapies in Patients with FSGS

219 Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis
Ruth J. Pepper, Dimitrios Chanouzas, Ruth Tarzi, Mark A. Little, Alina Caisian, Michael Walsh, Charles D. Pusey, Lorraine Harper, and Alan D. Salama, European Vasculitis Study (EUVAS) investigators
Diabetes and The Kidney

225 Effect of Spironolactone and Amiloride on Thiazolidinedione-Induced Fluid Retention in South Indian Patients with Type 2 Diabetes
Vijay Viswanathan, Viswanathan Mohan, Poongothai Subramani, Nandakumar Parthasarathy, Gayathri Subramaniyan, Deepa Manoharan, Chandru Sundaramoorthy, Luigi Gnudi, Janaka Karalliedde, and Giancarlo Viberti

Epidemiology and Outcomes

233 Albuminuria and Rapid Loss of GFR and Risk of New Hip and Pelvic Fractures
Joshua I. Barzilay, Peggy Gao, Catherine M. Clase, Andrew Mente, Johannes F.E. Mann, Peter Sleight, Salim Yusuf, and Koon K. Teo, on behalf of the OnTARGET/TRANSCEND Investigators

241 Model Comparisons of Competing Risk and Recurrent Events for Graft Failure in Renal Transplant Recipients
Ingvar Holme, Bengt C. Fellström, Alan G. Jardine, Anders Hartmann, and Hallvard Holdaas

248 Association of Physical Activity with Survival among Ambulatory Patients on Dialysis: The Comprehensive Dialysis Study
Kirsten L. Johansen, George A. Kaysen, Lorien S. Dalrymple, Barbara A. Grimes, David V. Glidden, Shuchi Anand, and Glenn M. Chertow

ESRD and Chronic Dialysis

254 Dialysis Modality and Correction of Uremic Metabolic Acidosis: Relationship with All-Cause and Cause-Specific Mortality
Tania Vashistha, Kamyar Kalantar-Zadeh, Miklos Z. Molnár, Klara Torlén, and Rajnish Mehrotra
See related editorial on page 177.

265 Early Dialysis Initiation and Rates and Timing of Withdrawal From Dialysis in Canada
Amanda D. Ellwood, S. Vanita Jassal, Rita S. Suri, William F. Clark, Yingo Na, and Louise M. Moist
See related editorial on page 179.

271 Effect of Oral Anabolic Steroid on Muscle Strength and Muscle Growth in Hemodialysis Patients
Ouppatham Supasyndh, Bancha Satirapoj, Pornanong Aramwit, Duangkamol Viroonudomphol, Amnart Chaiprasert, Vipa Thanachatwej, Supat Vanichakarn, and Joel D. Kopple

Mineral Metabolism/Bone Disease

280 Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients
Rudolf P. Wüthrich, Michel Chonchol, Adrian Covic, Sylvain Gaillard, Edward Chong, and James A. Tumlin

Renal Transplantation

290 Pregnancy in Renal Transplant Recipients: A UK National Cohort Study
Kate Bramham, Cathay Nelson-Piercy, Haiyan Gao, Matthias Pierce, Naomi Bush, Patsy Spark, Peter Brocklehurst, Jennifer J. Kurinczuk, and Marian Knight
See related editorial on page 182.

Controversies in Nephrology

299 PTH—A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients?
Giorgia Garrett, Sunita Sardiwal, Edmund J. Lamb, and David J.A. Goldsmith
See related rebuttal on page 321.

313 The Case for Routine Parathyroid Hormone Monitoring
Stuart M. Sprague and Sharon M. Moe
See related rebuttal on page 319.
Controversies in Nephrology (Continued)

319  Rebuttal: The Case for Routine Parathyroid Hormone Monitoring  
David J.A. Goldsmith  
See related article on page 313.

321  Rebuttal: PTH—A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients?  
Stuart M. Sprague and Sharon M. Moe  
See related article on page 299.

In-Depth Reviews

322  Searching for Uremic Toxins  
Mirela Dobre, Timothy W. Meyer, and Thomas H. Hostetter

328  Management of Crush Victims in Mass Disasters: Highlights from Recently Published Recommendations  
Mehmet Sukru Sever and Raymond Vanholder

Public Policy Series

336  Effect of the 2012 Election on Health Policy Issues for the Nephrologist  
Robert J. Rubin

On the Cover
What’s the diagnosis? Urine uric acid crystals as viewed under non-polarized (left side) and polarized (right side) illumination (400× magnification). Uric acid crystals form in acidic urine, typically pH < 6.0, and elevated urine uric acid is not always present. Uric acid crystals are most often rhomboid plates, as seen in the figure, or rosettes as opposed to the needle shaped monosodium urate crystals found in joint fluid of patients with acute gouty arthritis. Under non-polarized light urine uric acid crystals are colorless or may have may have a yellow or reddish-brown hue; under polarized light they appear polychromatic. (Image and text provided by Paul M. Palevsky, MD, FASN, Renal Section, VA Pittsburgh Healthcare System and Renal-Electrolyte Division, University of Pittsburgh School of Medicine, Pittsburgh, PA)